Haematopoietic stem cell transplant (HSCT) is an established intervention to augment bone marrow function, generate functional cells in immune deficiency syndromes and haemoglobinopathies, and treat...

These are exciting times for people with haemophilia and the health care professionals responsible for their management, with a number of new treatment options that have recently been approved by...

Primary immune thrombocytopenia (ITP) is a well-recognized autoimmune bleeding disorder characterized by isolated thrombocytopenia.1–3 Defective production or increased destruction of platelets4...

Cold agglutinin disease (CAD) is a rare type of autoimmune hemolytic anemia characterized by chronic hemolysis.1 CAD usually affects people between the ages of 40 and 80 years. The median age at ...

The 2022 Biotechnology Innovation Organization (BIO) International Convention The BIO International Convention took place in San Diego, CA, on 13–16 June 2022. BIO is the world’s largest advocacy...

Thrombotic thrombocytopenic purpura (TTP) is a life-threatening blood disorder that occurs in 2 to 11 cases per million people.1–4 TTP is characterized by a severe deficiency in the enzyme von...

Novel therapies for the treatment of Chronic Lymphocytic Leukemia have increased the availability of treatment options to patients and physicians. However, these drugs often require continuous...

The volume and diversity of real-world data have been growing exponentially as technology and integrated electronic medical records, and patient and physician surveys, have made this information...

The World Federation of Hemophilia (WFH) 2018 World Congress: Bayer Satellite Symposium   The XXXIII WFH World Congress took place in Glasgow, UK, on 20–24 May 2018.1  Founded by the World...